Last reviewed · How we verify
Indapamide (T2)
Indapamide is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule of the kidney, reducing blood volume and lowering blood pressure.
Indapamide is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule of the kidney, reducing blood volume and lowering blood pressure. Used for Hypertension, Edema associated with congestive heart failure.
At a glance
| Generic name | Indapamide (T2) |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | Thiazide-like diuretic |
| Target | Sodium-chloride cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Indapamide works primarily by blocking the sodium-chloride cotransporter in the distal convoluted tubule, leading to increased urinary sodium and water excretion. This reduces intravascular volume and peripheral vascular resistance, thereby lowering blood pressure. It also has mild vasodilatory properties independent of its diuretic effect.
Approved indications
- Hypertension
- Edema associated with congestive heart failure
Common side effects
- Hypokalemia
- Hyperglycemia
- Hyperuricemia
- Dizziness
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indapamide (T2) CI brief — competitive landscape report
- Indapamide (T2) updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI